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A monoclonal antibody (mAb), E25, is described that binds to the surface of cultured human endothelial cells. Upon 
binding E25 is rapidly internalized and digested intracellularly. Selective liposome targeting to the surface of the cells 
is performed using a biotinylated E25 antibody and an avidin-biotin system. Up to 30% of the ceil-adherent liposomal 
lipid is internalized. 
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1. INTRODUCTION 
Liposomes can be used as containers to deliver 
physiologically active substances to living cells [ 11. 
Despite the achievement of a high degree of 
liposome-cell association in some investigations 
[2,3], the problem of delivering the liposomal con- 
tents into the cell cytoplasm still exists. It is well 
known that in many cases only intracellular 
liposome delivery is required to cause effective 
pharmacological action of intraliposomal drugs on 
cells [4,5]. The problem is of particular importance 
for cells possessing low phagocytic activity, e.g. 
human vessel endothelial cells (EC). These cells are 
in direct contact with the blood and possess the 
unique property of exchanging macromolecular 
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DPPE, p-hydroxyphenylpropionylamido-DPPE; ILC, im- 
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substances with underlying tissues [6]. Hence, the 
targeting of biologically active substances to EC 
may result in a considerable biological effect. The 
application of monoclonal antibodies against cer- 
tain cell surface antigens can provide specificity 
and variety in liposome targeting and increased in- 
tracellular delivery (71. 
Here, we describe mAb E25 which is rapidly in- 
ternalized upon binding to cultured EC. A suc- 
cessful attempt was made to use this antibody as a 
mediator for cell surface binding and subsequent 
intracellular uptake of liposomes bound to mAb 
via an avidin-biotin bridge. 
2. MATERIALS AND METHODS 
2.1. Antibodies and cells 
Murine mAb E25 (IgGI) were obtained by conventional 
techniques after immunization of mice with EC from human 
umbilical vein [8]. Purified mAbs E25 were labeled with “‘1 (91 
and modified with biotin-LC-hydroxysulfosuccinimide ester 
(Pierce). EC were cultivated as in [lo]. 
2.2. Internalization of mAbs 
A microtest plate with EC monolayers was ice-cooled, the 
wells rinsed with cold medium 199 (M199) supplemented with 
10% calf serum (Flow Labs) and then 0.6 gg E25 in 30 pl Ml99 
were added. After incubation for 1.5 h at 4°C. EC were washed 
with Ml99 and transferred to a CO2 incubator at 37°C. After 
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appropriate time intervals the incubation medium was removed 
and EC immediately cooled in ice. Then 0.15 pg HRPO- 
conjugated rabbit anti-mouse antibodies in 30~1 Ml99 were 
added. After 1 h at 4°C excess conjugate was washed out and 
the plate processed for determination of HRPO substrate ab- 
sorbance (4~s) 1111. The rate of tz51-mAb degradation was 
determined following the appearance of radioactivity in the 
trichloroacetic acid-soluble fraction of the culture medium as 
described [12]. 
2.3. Liposomes and ILC 
BAC-DPPE was synthesized according to [13]. ‘251-labeled 
HPA-DPPE was prepared as in [14]. Liposomes composed of 
DPPC (Sigma), BAC-DPPE and HPA-DPPE at a molar ratio 
of 18 : 1 : 1 were sonicated in a probe-type sonicator (Lab-Line 
Instruments) for 5 min at 55°C and 50 W. The specific activity 
of the preparation was 3 x 10s cpm/pg total lipid. To prepare 
ILC 4 gg avidin D (Vector Labs) were added to 260 pl liposome 
suspension in Eagle’s culture medium supplemented with 
2 mg/ml bovine serum albumin (ECM, 40 pug lipid per ml) with 
subsequent addition of 3 fig biotinylated antibodies. ILC (34 pg 
lipid in 25 pl ECM) were added to ice-cold EC monolayers in 
a microtest plate and incubated for I h at 4°C. Non-bound ILC 
were removed by extensive washings. Fresh medium was added 
and EC incubated at 37°C for 1 h, followed by cooling in ice. 
25 pl avidin-HRPO (Vector Labs) in ECM were added to each 
well and incubated for 1 h at 4°C. The EC monolayers were 
rinsed and processed for A490 monitoring and counting of “‘I. 
3. RESULTS AND DISCUSSION 
The mAb E25 binds to cultures of living and 
formaldehyde-treated EC from human umbilical 
vein. Binding of E25 to EC does not depend on 
monolayer preincubation (1 h, 25°C) with human 
plasma (fig.1) or incubation in the presence of 
whole blood (not shown). No binding of E25 to 
several other purified components of the ex- 
tracellular matrix (human plasma fibronectin, type 
IV and V collagens) was observed. 
Using an HRPO-labeled, second antibody it was 
revealed that surface-bound E25 rapidly disap- 
pears from the cell surface at 37°C (fig.2). The 
amount of surface-bound antibodies detectable 
was reduced by a factor of two within 30 min. 
‘251-labeled mAbs E25 were incubated with EC 
and the kinetics of degradation of the internalized 
mAb was followed by analysis of the distribution 
of radioactive label in acid-soluble and acid- 
insoluble fractions of the culture medium. A con- 
tinuous decrease in acid-precipitable radioactivity 
and concomitant accumulation of acid-soluble 
protein remnants were observed throughout the 
180 min incubation period (fig.3). Cell-bound 
radioactivity, however, remained constant. Thus, 
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Fig.1. Binding of mAb E25 to cultured human EC (4°C) 
revealed using enzyme-labeled antimouse antibody. (1) Binding 
after 1 h incubation in human plasma, (2) binding without 
incubation with human plasma, (3) binding of non-specific 
mouse IgG to EC (control). 
internalized antibodies were digested in in- 
tracellular compartments and degraded antibody 
fragments (acid-soluble fraction) could then be 
found in the culture medium. Moreover, the rate 
of antibody internalization was comparable to its 
rate of intracellular degradation. Similar tests with 
formaldehyde-fixed EC revealed no apparent 
changes in E25 binding to the cell surface, while all 
12? radioactivity was precipitated by trichloro- 
acetic acid. It seems reasonable to conclude that in 
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Fig.2. Internalization of ‘ZsI-mAb E25 by cultured human EC 
at 37°C as revealed with enzyme and radioactive labels. (1) EC 
surface-bound ‘*‘I-E25, (2) total EC-associated ‘*‘I-E25, (3) 
total binding of ‘Z51-labeled mouse IgG (control). 
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Fig.3. Kinetics of the degradation of ‘*‘I-E25 in cultured EC. 
(1) Total EC-associated ‘251-E25, (2) “‘1 label in acid-soluble 
fraction, (3) “‘1 label in acid-precipitated fraction, (4) total “‘1 
radioactivity in culture medium. 
living EC antibody-antigen complexes are sub- 
jected to active internalization and degradation. 
Liposomes adhering non-specifically to the EC 
surface are not endocytosed. This was tested in ex- 
periments similar to those of the antibody inter- 
nalization studies, except that avidin-HRPO was 
used instead of the second enzyme-labeled an- 
tibody. Hence, intracellular targeting of un- 
modified liposomes into EC cells is ineffective 
(fig.4). 
The modification of liposomes with non-specific 
IgG in order to achieve targeting via Fc receptors 
as in [15] was also ineffective (fig.4). Liposomes 
were coated with biotinylated IgG via the avidin- 
biotin bridge technique. When biotinylated mAb 
E25 was used for ILC preparation (ILC-E25) it 
was demonstrated that the amount of EC- 
associated lipid increased lo-fold in comparison 
with liposomes bearing biotinylated, non-specific 
mouse IgG (ILC-IgG) or unmodified liposomes 
(fig.4). Up to 3 ng lipid per microtest well were 
bound as ILC-E25, equivalent to approx. 1000 
liposomes of diameter 0.1 pm per cell [16]. When 
the temperature was increased from 4 to 37°C a 
pronounced decrease in the amount of surface- 
bound ILC was observed. At 37°C about 30% of 
ILC-E25 are internalized, whereas only 70% of the 
ILC-E25 remain on the cell surface. 
It should be mentioned that the targeted delivery 
described here is highly specific, since it is 
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Fig.4. Total and surface binding of ILC to EC culture revealed 
by determinations of ‘251 and A490 after incubation of ILC with 
EC at 4°C (A) and after 1 h incubation at 37°C (B). 
mediated by antigen-antibody interactions. This 
provides some advantages over the Fc receptor 
targeting systems reported earlier [15]. There are 
some indications in the literature that EC may be 
involved in targeted cancer chemotherapy aimed at 
preventing the neovascularization of tumors [ 171. 
Since mAbs E25 bind to endothelium in the 
presence of serum or blood, the system described 
may be considered as a first step towards the 
targeting of biologically active substances into the 
EC in vivo. Detailed studies of the antigen 
recognized by mAb E25 and the structure of ILC 
are now in progress. 
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